Vistin Pharma ASALTS:0RAM 77 Interest Coverage is 3.90 as of Mar. 2026, which is 94% below its 10-year median of 66.60. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 685 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 60.58% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Vistin Pharma ASA's
Operating Income
for the
three
months ended in Mar. 2026 was kr21.5 Mil. Vistin Pharma ASA's Interest Expense for the
three
months ended in Mar. 2026 was kr-5.5 Mil.
Vistin Pharma ASA's interest coverage for the quarter that ended in Mar. 2026 was 3.90.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Vistin Pharma ASA's Interest Coverage or its related term are showing as below:
LTS:0RAM'
s Interest Coverage Range Over the Past 10 Years
Min: 7.54 Med: 66.6 Max: 391.66
Current: 7.54
LTS:0RAM's Interest Coverage is ranked worse than 60.58% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs LTS:0RAM: 7.54
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Vistin Pharma ASA Interest Coverage Related Terms
Vistin Pharma ASA Interest Coverage Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0RAM vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a Interest Coverage of 3.90 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vistin Pharma ASA and its competitors. This is 94% below median its historical median of 66.60. Over the past decade, Vistin Pharma ASA's Interest Coverage has ranged from 7.54 to 391.66. According to the industry distribution chart, Vistin Pharma ASA ranks #415 out of 685 companies in the Drug Manufacturers industry, placing it in the top 60.6%.
Is Vistin Pharma ASA's Interest Coverage too high?
Vistin Pharma ASA's current Interest Coverage of 3.90 is 94% below median its 10-year median of 66.60. Over the past 10 years, this metric has ranged from a low of 7.54 to a high of 391.66. The Drug Manufacturers industry median Interest Coverage is 12.75. Vistin Pharma ASA's value of 3.90 is 69.4% below this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #415 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #415 out of 685 companies for Interest Coverage. This places Vistin Pharma ASA in the lower half of its industry. The industry median Interest Coverage is 12.75. Vistin Pharma ASA's value of 3.90 is 69.4% below this benchmark. Historically, Vistin Pharma ASA's own Interest Coverage has ranged from 7.54 to 391.66 over the past decade. While the company's 10-year median is 66.60 vs. the industry median of 12.75, Vistin Pharma ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Interest Coverage of 3.90 is 69.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Interest Coverage is 3.90, which is 94% below median its own 10-year median of 66.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Interest Coverage is 3.90, which is 94% below median its 10-year median of 66.60 and 69.4% below the Drug Manufacturers industry median of 12.75. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Interest Coverage is 3.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Interest Coverage: 3.90 (94% below median its 10-year median of 66.60)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 69.4% below the Drug Manufacturers median (#415 of 685)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
